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Abstract
Background: In this chart review, we attempted to evaluate the benefits of adding aripiprazole in veterans with
military-related PTSD and comorbid depression, who had been minimally or partially responsive to their existing
medications.
Methods: A retrospective chart review of patients who received an open-label, flexible-dose, 12- week course of
adjunctive aripiprazole was conducted in 27 military veterans meeting DSM-IV criteria for PTSD and comorbid
major depression. Concomitant psychiatric medications continued unchanged, except for other antipsychotics
which were discontinued prior to initiating aripiprazole. The primary outcome variable was a change from baseline
in the PTSD checklist-military version (PCL-M) and the Beck Depression Inventory (BDI-II).
Results: PTSD severity (Total PCL scores) decreased from 56.11 at baseline to 46.85 at 12-weeks (p < 0.0001 from
Wilcoxon signed rank test) and the depression severity decreased from 30.44 at baseline to 20.67 at 12-weeks (p <
0.0001 from Wilcoxon signed rank test). Thirty seven percent (10/27) were considered responders, as defined by a
decrease in total PCL scores of at least 20 percent and 19% (5/27) were considered as responders as defined by a
decrease in total BDI score of at least 50%.
Conclusions: The addition of aripiprazole contributed to a reduction in both PTSD and depression
symptomatology in a population that has traditionally demonstrated poor pharmacological response. Further
investigations, including double-blind, placebo-controlled studies, are essential to confirm and further demonstrate
the benefit of aripiprazole augmentation in the treatment of military related PTSD.
Background
Military-related posttraumatic stress disorder (PTSD) is
a serious psychiatric condition often resulting from
combat duty in the current wars in Afghanistan and
Iraq [1] and past peacekeeping and humanitarian mis-
sions [2-4]. Patients with PTSD present with four symp-
tom clusters: reexperiencing of the traumatic event(s),
avoidance of reminders and emotional numbing (which
are grouped together as one symptoms cluster in DSM-
IV, but are seen as distinct and will likely be denoted as
such in DSM-V), and hyperarousal symptoms [5,6].
Recent estimates of the prevalence of PTSD in various
military and veteran populations have varied from a low
of 4.8% in UK military members [7], to 10.3% in Cana-
dian peacekeeping veterans, [8] and 11.2 - 17.1% in U.S.
military members returning from the deployments to
Iraq and Afghanistan [9]. Military-related PTSD is asso-
ciated with severe psychosocial dysfunction [10,11].
The therapeutic response to pharmacological interven-
tions for military-related PTSD is often disappointing
[10,12-16]. PTSD often presents with co-morbidities
such as depression and substance abuse or dependence
[17,18]. Amongst veterans, the comorbidity rates may be
much higher than in other populations [19,20]. Studies
have also demonstrated that veterans with chronic, mili-
tary-related PTSD often present with significant comor-
bid psychotic features [21,22] which may contribute to
the severe psychosocial dysfunction in this population
[10,11].
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Selective Serotonin/Norepinephrine Reuptake Inhibi-
tors (SNRIs) have the most empirical evidence for effi-
cacy in the treatment of PTSD and are usually
considered first-line treatment [5,16,23]. SSRIs and
SNRIs are also effective agents for the treatment of co-
morbid mood and anxiety disorders commonly asso-
ciated with PTSD. However, the lack of efficacy of
antidepressant monotherapy, especially in male combat
veterans, [24,25] has led to the frequent use of combi-
nation strategies, especially the addition of antipsycho-
tics, in many treatment guidelines for treatment-
resistant PTSD [5,26].
The benefit of adding a second-generation antipsy-
chotic, such as risperidone, quetiapine, or olanzapine
for the treatment of PTSD in combination with a pri-
mary antidepressant has been suggested in numerous
small studies, including a few randomized controlled
trials [27-30]. These agents appear beneficial in mana-
ging hyperarousal symptoms such as hypervigilance
and irritability, as well as severe dissociative symptoms
[16]. There is also evidence for the addition of aripi-
prazole, quetiapine, risperidone, and olanzapine for
treatment-resistant depression, [31] which often pre-
sents as a complicating factor in military-related,
chronic PTSD. More recently, the efficacy of aripipra-
zole in the treatment of PTSD has been demonstrated
in three preliminary open-label studies in veteran
populations, both as a monotherapy and as an adjunc-
tive treatment [32-34].
Aripiprazole is a novel antipsychotic with partial ago-
nist activity at D2 receptors and 5HT1A receptors, and
antagonist activity at 5-HT2A receptors [35]. Aripipra-
zole is reported to have less risk for extrapyramidal side
effects than traditional antipsychotics [36,37] and has
been demonstrated to be effective in treatment-resistant
depression [38,39].
Based on the positive results of aripiprazole for both
treatment-resistant depression and treatment-resistant
PTSD, and on its unique pharmacology, we hypothe-
sized that aripiprazole would be efficacious for treat-
ment-resistant military-related PTSD with comorbid
major depression. To reflect general clinical practice,
we conducted a retrospective file review to examine
the benefits of adding aripiprazole in veterans with
military-related PTSD and comorbid depression, who
had been minimally or partially responsive to their
existing medications. To our knowledge, this is the
first attempt to examine the efficacy of aripiprazole to
treat both chronic PTSD and comorbid depression in a
sample of veterans with chronic military-related PTSD
where all of the participants had comorbid major
depression.
Methods
Participants and Procedure
Participants consisted of a sample of 27 out of 123 con-
secutive veterans who consented to try aripiprazole aug-
mentation between November 2009 and August 2010.
All patients were receiving outpatient psychiatric care at
a clinic specializing in the assessment and treatment of
military-related psychiatric conditions. The clinic follows
a standardized assessment and treatment protocol; the
standardized assessments included the PTSD Checklist-
Military Version (PCL-M), [40] Beck Depression Inven-
tory (BDI), [41] and Medical Outcomes Study (MOS)
36-item Short-Form Health Survey (SF-36), [42] admi-
nistered at intake and at each follow-up appointment
over the course of treatment. In addition to providing
psychoeducation, the standard psychiatric treatment at
the clinic includes symptom management, treatment of
comorbid disorders, and management of functional
impairment [5]. Participants were prescribed aripiprazole
after demonstrating minimal or partial response to their
existing antidepressant and/or minimal or partial
response to other antipsychotic augmentation strategies.
All subjects received a comprehensive psychiatric eva-
luation and laboratory tests (complete blood count with
white count differential, serum electrolytes, glucose,
creatinine, blood urea nitrogen, liver function tests, and
lipid profile). The initial dose of aripiprazole was 2 to 5
mg daily, with further dose titrations based on tolerabil-
ity and clinical response, up to a maximum of 30 mg
daily. Efficacy and adverse effects were assessed and
recorded at each follow-up appointment (bi-weekly for
the first month and then monthly). Antidepressants,
anxiolytics, and mood stabilizers were allowed but had
to be kept at a constant dose during the 12- weeks
treatment phase. As we were specifically interested in
examining the benefits of aripiprazole augmentation in
veterans with military-related PTSD, patients not pre-
scribed aripiprazole augmentation were excluded from
this chart review. For patients who were already pre-
scribed an antipsychotic, the antipsychotic was discon-
tinued prior to the initiation of aripiprazole.
The sample was derived from a retrospective chart
review with approval from the Office of Research
Ethics of the University of Western Ontario. Consent
from each patient was not obtained specifically for this
chart review. However, as part of the initial orientation
to the clinic, all patients are asked to provide written
consent to participate in research. All patients met the
DSM-IV criteria for PTSD and comorbid major
depressive disorder. To maximize the generalizability
of this evaluation to usual “clinical practice,” all
comorbid physical and psychiatric conditions were
included in the chart review.
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To diagnose PTSD, the Clinician-Administered PTSD
Scale (CAPS) [43] was administered by a trained clini-
cian and the diagnosis of major depressive disorder was
determined using the Patient Health Questionnaire
(PHQ-9)[44] and the psychiatric interview according to
the Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition (DSM-IV) criteria [6]. To assess
change in PTSD symptoms with treatment, the PCL-M
[40] was used. Similarly, the BDI [45,46] was used to
assess change in depressive symptoms as a result of
treatment. The SF-36 [47] was used to assess health
related quality of life (HRQol). The SF-36 measures
functional impairment in eight domains or subscales;
the mental health sub scales can be collapsed into the
Mental Component Summary (MCS) Score reflecting
overall mental health [48]. The PCL-M, the BDI, and
the SF-36 were all administered at each follow-up
appointment including at intake (t1) and at 1-, 2-, and
3-month follow-ups (t2, t3, and t4) over the course of
treatment. The total PCL-M and the total BDI were the
primary efficacy variables; the total PCL-M re-experien-
cing, avoidance/numbing, and hyperarousal subscale
scores served as secondary efficacy variables.
Analysis
The LOCF data for each visit included the data recorded
at that visit or carried forward from the last visit. For
the primary outcome, the Wilcoxon signed rank test
and effect sizes (Cohen’s d) was used to determine the
statistical significance of the change from baseline total
PCL-M and Total BDI score at each follow-up time
point (t2, t3, t4). For the three secondary outcome mea-
sures (the PCL-M reexperiencing, avoidance/numbing,
and hyperarousal subscale scores), only the effects at t4
were examined. To correct for multiple comparisons, we
used Hochberg step-up multiple comparisons procedure
[49].
For each of the two main outcomes, we identified
responders on our two outcome measures using criteria
established in existing literature. More specifically, on
the PCL, we identified those with at least a 20% reduc-
tion in their total PCL scores as responders; [33] this is
in keeping with prior treatment efficacy and more speci-
fically, prior Aripiprazole treatment efficacy studies for
PTSD [33]. On the BDI, we identified those with at least
a 50% reduction in their symptom scores as responders
[50].
Results
Demographics and Clinical Characteristics
Demographic and clinical characteristics of the sample
are presented in Table 1. Of the 27 participants, almost
all were men (n = 26, 96.3%), with an average age of
39.36 years (SD = 5.98) and an average of 10.26 years
(SD = 7.38) with PTSD symptoms. At intake, the major-
ity (n=2 0 , 74.1%) of the sample had been released
from the military. Years of military service averaged
15.04 years (SD = 7.41). Almost all (n = 26, 96.3%) had
exposure to combat or to a war zone during their
deployment and the most common deployments
reported were Afghanistan (n = 9, 33.3%), the former
Yugoslavia (n = 8, 29.6%), and Africa (Somalia, Rwanda,
Eatrea, and Sierra Leone) (n =5 ,1 8 . 5 % ) .A l lp a t i e n t s
were taking an antidepressant prior to initiating aripi-
prazole, most commonly a norepinephrine dopamine
reuptake inhibitor (NDRI) (n = 16, 59.3%), followed by
noradrenergic specific serotonergic antidepressants
(NaSSA) (n = 12, 44.4%); serotonin norepinephrine
reuptake inhibitor (SNRI) (n = 11, 41.7%), and selective
serotonin reuptake inhibitor (SSRI) (n = 10, 37%). Most
patients (n = 14, 51.9%) were taking two antidepressant
and an additional 14.8% (n = 4) were taking three anti-
depressant. In addition to an antidepressant, 8 patients
(30.77%) were prescribed an anticonvulsant, 5 patients
(19.23%) were prescribed a stimulant, and 4 patients
(15.38%) were prescribed a hypnotic.
Twenty-seven patients had at least one post-baseline
efficacy evaluation thus were included in the efficacy
analysis. At intake, all participants met full criteria for
PTSD based on the CAPS interview. The average dura-
tion of PTSD symptoms was 10.26 years (SD = 7.38),
suggesting a chronic course for this sample. Intake
scores on the PCL-M and the BDI averaged 56.11(SD =
12.66) and 30.44 years (SD = 7.86), respectively. On the
PCL-M, a score of 50 is the conventional cut-off score
for a positive screen for PTSD in veteran populations;
[51] on the BDI, scores above 29 are considered indica-
tive of severe depression [52]. SF-36 MCS and PCS were
Table 1 Baseline characteristics of the sample
Demographic and clinical variables n (%) or mean (sd)
Age 39.36 (6.09)
Sex
Male 26 (96.30%)
Female 1 (3.70%)
Canadian Forces (CF) status
Released 20 (74.07%)
Still serving 7 (25.93%)
Current Work Status
Unemployed 17 (62.96%)
Working for Pay 6 (22.22%)
On Sick Leave from Work 4 (14.81%)
Duration of illness 10.26 (7.38)
SF-36 Mental component score 20.22 (10.11)
SF-36 Physical component score 32.48 (15.06)
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indicating significant impairment in scales measuring
both mental and physical functioning.
Dose and Tolerability
The final average dose of aripiprazole was 12.40 (SD =
4.35) mg daily. The mean value of weight decrease from
baseline (mean = 99.25 kg, SD = 13.35) to the final visit
is 1.05 kg (SD = 4.95). Only two patients discontinued
the aripiprazole; one patient due to non-response and
one due to intolerable restlessness. The remaining 25
patients tolerated the aripiprazole. The most common
side effects reported were insomnia (N = 5/27, 18.5%);
agitation/irritability (N = 4/27, 14.8%); restlessness (N =
3/27, 11.1%); and fatigue (N = 2/27, 7.4%). The good
tolerability was likely related to lower starting doses (2
mg daily) and slow titration (increasing the dose by 2-5
mg every two weeks).
Treatment Efficacy
Results from Wilcoxon signed rank tests showed sig-
nificant decreases between baseline and each of the
three follow-ups for the BDI and the PCL, as well as
the last visit for the PCL Reexperiencing, Avoidance,
and Hyperarousal subscales (Table 2), even after multi-
ple testing correction. The total PCL score decreased
from 56.11 (SD = 12.66) at baseline to 46.85 (SD =
13.53) at three months and the total BDI score 30.44
(SD = 7.85) at baseline to 20.67 (SD = 10.05) at three
months, figure 1. Effect sizes and changes in the clini-
cal outcome variables from intake to the final visit are
reported in Table 3.
The number and percentage of responders at each of
the follow-ups are reported in Table 4. Thirty seven per-
cent (10/27) were considered responders, as defined by a
decrease in total PCL scores of at least 20 percent and
for depression, 19% (5/27) were considered responders
as defined by a decrease in total BDI score of at least
50%. Overall, a higher percentage of participants met
criteria for being a responder on the PCL than the BDI.
Additional analyses to examine the efficacy of aripi-
prazole among those with severe depression (BDI > 29)
at intake (n = 14) found significant reductions in PCL
symptom scores for this subsample as well, with the
PCL scores averaging 61.79 (SD = 9.60), 51.86 (SD =
13.54), 52.14 (SD = 15.53), and 48.71 (SD = 13.02) at
intake and each of the follow-ups, respectively. The Wil-
coxon signed rank test results showed significant reduc-
tions from intake to each of the follow-ups (p = 0.0051,
p = 0.0405, and 0.0010 for each of the follow-ups). The
percentages of responders on PCL at each of the follow-
ups are 35.71%, 42.86%, and 57.14%, respectively. It is
worth noting that at t4, having severe depression was
found to be associated with higher percentage of
responders on PCL (P = 0.0461 from Fisher’s exact test).
Discussion
Consistent with previous studies in veterans, [32-34] the
addition of aripiprazole contributed to a reduction in
PTSD symptomatology in all symptom clusters (reexper-
iencing, avoidance/numbing, and hyperarousal) and
among those with severe comorbid major depression dis-
order (baseline BDI ≥ 29). A significant number (37%)
demonstrated a significant reduction in PTSD symptoma-
tology (decrease in total PCL scores of at least 20%). Also
consistent with studies on treatment resistant depression,
[53,54] the addition of aripiprazole demonstrated an over-
all reduction in depression severity from a total BDI score
of 30.44 at baseline to 20.67 at three months.
Table 2 Wilcoxon signed rank test between intake and
each of the follow-ups
Outcomes p-value
BDI
Difference between baseline and t2 0.0179
Difference between baseline and t3 0.0042
Difference between baseline and t4 <0.0001
PCL
Difference between baseline and t2 0.0061
Difference between baseline and t3 0.0016
Difference between baseline and t4 <0.0001
Reexperiencing subscale
Difference between baseline and t4 0.0020
Avoidance subscale
Difference between baseline and t4 0.0123
Hyperarousal subscale
Difference between baseline and t4 0.0043
BDI: Beck Depression Inventory
PCL: PTSD Checklist
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Figure 1 Change in PCL and BDI total score from baseline (t1)
to 3 months (t4) for patients receiving aripiprazole.
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this chart review, when compared to the augmentation
trial by Roberts and colleagues [33], might be related to
higher rates of comorbid depression (100%) in this
patient group. Furthermore, unlike the study by Berman
[55] where 42% met the criteria for significant decrease
in depression severity, in our chart review only a minor-
ity (19%) showed decrease in total BDI scores of at least
50%. The low response rate observed in our chart
review compared to Berman and colleagues’ [55] study
might be related to the fact that in Berman’ss t u d y ,
patients with comorbid PTSD were excluded. Also in
this chart review, most patients (52.9%) reported depres-
sion in the severe range and most patients (n = 18,
66.7%) in this sample continue to be symptomatic
despite being prescribed combination antidepressant
prior to initiating aripiprazole, suggesting significant
treatment resistance. Although modest, the response
rate is particularly encouraging in a population of
chronic military-related PTSD with comorbid major
depression in the severe range, which has traditionally
demonstrated poor response to pharmacotherapy. Clini-
cally, it stresses the importance of encouraging patients
to persist with treatment and to consider augmentation
strategies for patients who demonstrate a partial
response (25-50% improvement) or no response with
optimization of monotherapy.
Due to significant limitations of this chart review,
including a small sample size, the retrospective nature
of the design, and a lack of a control group, careful
interpretation of the findings is warranted. This was a
preliminary, open-label retrospective chart review, with
a small sample size. However, since most patients in
this chart review had PTSD for more than 10 years,
with comorbid major depression in the severe range, the
observation that the majority of patients had improved
scores for both PTSD and depression severity is
noteworthy.
Conclusions
Military-related PTSD often presents with comorbid
major depression requiring prompt and effective treat-
ment. This chart review demonstrates that the addition
of aripiprazole can assist in providing symptom relief in
a population that has traditionally demonstrated poor
pharmacological response. Further studies including
double-blind, placebo-controlled studies are necessary to
confirm our findings and further demonstrate the bene-
fit of aripiprazole augmentation in the treatment of mili-
tary- related PTSD.
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